Scottsdale & Glendale, Arizona
Find out whether additional support could make a difference in your recovery. HBOT research offers encouraging findings for selected radiation injuries and difficult wounds after cancer treatment, alongside developing research on HBOT combined with cancer therapies.2, 5, 7
HBOT can have a role in care for selected treatment-related injuries. Its use to improve tumor control remains under investigation. It is not a stand-alone cancer treatment or a replacement for your oncology plan.
Support for the next part of your care
Radiation can leave some tissues with reduced blood supply and persistent injury months or years later. HBOT increases oxygen availability and is studied as a way to support repair. The most useful conversation starts with the specific problem affecting your daily life.4, 14
01 / Pelvic radiation injury
Randomized evidence and longer follow-up support considering HBOT for selected patients with chronic radiation cystitis. Improvements in urinary symptoms can be meaningful in everyday life.1, 2
02 / Breast and chest-wall effects
The HONEY trial reported reduced fibrosis after breast irradiation. Pain findings were more favorable in an analysis of women completing treatment, making suitability and the practical commitment part of the discussion.3
03 / Difficult wounds
Clinical reports describe healing of selected compromised wounds after breast cancer surgery. HBOT may be considered alongside surgical assessment, wound care, and an oncology plan.5
You do not need all the answers before contacting us. Bring your questions, your current care plan, and what you hope to understand. A consultation can help you weigh potential benefits, uncertainty, practical needs, and costs before making a treatment decision.
Research on treatment-related injury
These studies address recovery from selected effects of cancer treatment. Their outcomes concern symptoms and tissue healing, rather than treatment of the cancer itself.
Literature checked
September 11, 2026
RICH-ART trial · 2019 and 2025
Randomized initial comparison · follow-up of treated patients
The initial trial found greater improvement in patient-reported urinary symptoms with HBOT than with standard care. Its 2025 follow-up reported that average improvements remained evident up to five years after treatment.
The long-term analysis included 70 treated patients and had no continuing untreated control group because controls were offered HBOT. Five-year measurements were available for 39 patients. These findings are encouraging but do not mean everyone responds or that a five-year benefit is guaranteed.
Read the randomized trial Read the 2025 follow-upHONEY randomized trial · 2024
A trial of offering HBOT for persistent local symptoms
Offering HBOT reduced reported moderate or severe fibrosis, the tissue thickening or tightness that can follow radiation. An analysis accounting for treatment completion also found favorable pain outcomes among women likely to complete the course.
The primary randomized analysis did not show a significant pain reduction. Only 31 of 125 women offered HBOT completed it, with treatment intensity an important barrier. Findings among completers should not be presented as the result for everyone offered treatment.
Read the HONEY trialClinical wound series · 2025
20 patients · a single institution’s retrospective experience
A study of difficult post-mastectomy wounds reported complete healing in all 20 patients receiving adjunctive HBOT, allowing planned cancer therapies to continue. The wounds included flap problems and wound separation.
This was a selected, uncontrolled series with other care provided. Its results cannot establish HBOT’s independent effect or predict an RX-O2 success rate. Prompt surgical assessment remains essential for a newly compromised wound.
Read the wound-management studyA retrospective study of 19 selected patients reported improvement in at least one vaginal symptom in 15 patients after HBOT. Complaints included ulceration, pain, and tissue changes. There was no control group, and incomplete treatment courses were excluded. These are encouraging observations that need confirmation. Read the study.
Across 18 studies, the review found that HBOT may improve selected late radiation injuries, with low- to moderate-certainty evidence for several outcomes. Results varied by tissue and condition, and adverse effects such as ear-pressure injury and usually temporary visual changes were more common. The review supports careful patient selection rather than one approach for every radiation-related symptom. Read the Cochrane review.
A clinically focused review in CA: A Cancer Journal for Clinicians examines HBOT for chronic radiation-related effects, including fibrosis, cystitis, and proctitis. It emphasizes selecting the right patients, coordinating care, and considering treatment burden. Bowel-injury trials have produced differing results, so bladder findings should not be generalized to every pelvic symptom. Read the clinical review.
Developing oncology research
Low oxygen inside some tumors can contribute to treatment resistance. Researchers are investigating whether HBOT can improve responses when carefully combined with chemotherapy, radiation, or immunotherapy. This is a different clinical question from healing radiation-damaged tissue.9, 10
Glioma meta-analysis · 2026
Nine studies described as randomized trials · 837 patients
The authors reported favorable tumor-response and quality-of-life findings when HBOT was added to chemoradiotherapy for glioma. This adds to the reasons for studying oxygen as part of coordinated oncology treatment.
The findings require confirmation in large multicenter phase 3 trials. The published abstract was reviewed; the individual trials were not independently reassessed here. Glioma includes different tumor types, and these results do not establish routine HBOT for every glioblastoma patient or for other cancers.
Read the 2026 glioma meta-analysisA nine-patient pilot reported disease control at three months in five patients receiving HBOT followed by stereotactic re-irradiation. This specialized treatment sequence had no comparison group; one patient developed grade 3 radiation necrosis. It illustrates an investigational approach requiring radiation-oncology coordination, not a schedule to arrange independently at an outpatient clinic. Read the pilot study.
This review brings together laboratory work and small clinical reports exploring oxygen, treatment resistance, and combinations with radiotherapy or chemotherapy. It identifies promising directions while calling for prospective randomized confirmation. It is a map of heterogeneous evidence, not proof that HBOT alone controls glioblastoma. Read the scoping review.
A phase Ib/II study protocol describes combining HBOT with chemotherapy and a PD-1 inhibitor for advanced gastric or gastroesophageal-junction cancer. It is a research plan, not a report of successful treatment outcomes. No results were posted in the linked trial registry when checked on September 11, 2026. Read the protocol or view the registered study.
Laboratory findings
Lung cancer cells · 2026
In cell cultures exposed to high glucose, prolonged HBOT reduced stem-like features and reversed increased radiation resistance. This is laboratory evidence, not a patient trial or a proven lung-cancer treatment.
Read the cell-culture studyGlioblastoma cells and animal work · 2025
Researchers reported greater chemotherapy sensitivity alongside changes in hypoxia-related signaling. They also observed increased cell proliferation under some conditions. These complex findings support study of carefully chosen combinations, rather than assuming HBOT alone suppresses tumor growth.
Read the preclinical studyBring this research to your oncology team. A hyperbaric consultation can help clarify the question being asked, review relevant evidence, and discuss whether further specialist coordination is appropriate. Keep prescribed cancer treatment in place; do not change medicines or their timing to add HBOT.
Find newer cancer and HBOT research on PubMed. Results are sorted by publication date and have not necessarily been reviewed for this page. Reviews and follow-up reports can include the same patients.
An informed next step
Tell us what you hope to improve: a persistent wound, radiation-related tissue changes, bladder symptoms, or your understanding of emerging research. Your oncology team remains central to the plan.
We can review the relevant publications, your practical needs, and questions for the evaluating medical provider. Recent and past chemotherapy, lung conditions, surgery, and implanted devices may affect suitability and timing.16
New bleeding, a changing wound, or new symptoms should also be reported promptly to your treating clinician. These symptoms need assessment rather than being assumed to be radiation injury.19
The RX-O2 difference
From your first questions to each treatment visit, our Scottsdale and Glendale clinics focus on medical oversight, patient education, and attentive care.
Medical Director Marvin A. Borsand, DO, FACOS, FACCS, HCC, leads clinical oversight. A licensed medical provider evaluates suitability and prescribes treatment when appropriate.
Our facilities use prescription-level hyperbaric systems, with chamber selection and treatment settings matched to your prescribed plan.
You breathe oxygen through a dedicated mask or hood while the chamber is pressurized with air. Your technicians monitor you throughout treatment.
Our technicians are certified through the National Hyperbaric Safety Association and trained in chamber operations, patient monitoring, and emergency procedures.
From questions to a care plan
Bring your current treatment plan and the concerns affecting your daily life. Let us know which specialists are involved in your care.
A licensed medical provider reviews your history, medicine compatibility, and the specific goal of treatment. The evidence is matched to that goal.
If HBOT is appropriate, discuss visits, follow-up, costs, and coordination with your treating team before beginning.
Confirm suitability before purchasing. Our pricing and packages page shows current options. A consultation helps determine what, if any, treatment is appropriate and what practical commitment to expect.
Local care, two Valley locations
Looking for a hyperbaric consultation near Phoenix? RX-O2 offers two locations for patients across the Valley. Call the clinic closest to you for appointment availability and help planning repeat visits.
An East Valley option for patients in Scottsdale, Paradise Valley, Fountain Hills, and nearby communities.
A West Valley option for patients in Glendale, Peoria, Phoenix, and nearby communities.
Your questions are welcome
Bring your questions, your care plan, and the outcomes that matter to you.
HBOT has a clinical role in selected treatment-related tissue injuries. Research also explores combinations with cancer therapies, including glioma treatment, but it has not established HBOT as a stand-alone cancer treatment or cure. Your oncologist directs tumor treatment; an RX-O2 consultation can help explore the hyperbaric questions.
Yes, but a medical review and coordination with your oncology team must come before treatment. Current and past medicines matter, including drugs such as bleomycin, doxorubicin, and cisplatin, which can raise compatibility concerns. Do not stop medicines or change treatment dates yourself. There is no universal safe schedule for combining HBOT with every cancer regimen.16
Earlier clinical reviews did not identify a general increase in tumor growth or recurrence with HBOT. Laboratory responses vary by tumor model and treatment combination, so that finding is not a guarantee for every situation. Active cancer and your planned therapies require individualized oncology and hyperbaric review.13, 12
Late radiation injury can appear months or years after treatment. A consultation may be useful if your treating team has identified a persistent tissue problem. New symptoms still need appropriate evaluation to confirm the cause before deciding whether HBOT fits.14
No. The location and diagnosis matter. Bladder findings do not automatically apply to bowel symptoms, jaw injury, or neurological problems. For example, the 2024 ISOO-MASCC-ASCO jaw osteoradionecrosis guideline does not support routine HBOT because evidence is limited. A specialist can explain the recommendations that apply to your specific problem.15
Tell your oncology team about these symptoms so their causes can be assessed. The tissue-healing and tumor-combination studies summarized here do not establish HBOT as a treatment for all cancer-related fatigue, neuropathy, or cognitive symptoms. A consultation can help identify the question and the relevant evidence.19
RX-O2 uses FDA-cleared hard-shell chambers. You breathe 100% medical oxygen through a dedicated mask or hood while the chamber is pressurized with air. Physician-led care and NHSA-certified technicians support prescribed treatment. Possible risks include ear-pressure injury, temporary visual changes, and confinement anxiety; less common serious risks include oxygen-induced seizures and lung pressure injury. Staff review medicines, dressings, and devices for compatibility. Electronics and battery-powered devices are not allowed inside chambers.17, 18
Recommendations depend on the diagnosis, treatment goal, medical history, and response. There is no universal course for “cancer support.” Review pricing and packages with the team after medical assessment. Device clearance, published research, and a package listing do not guarantee insurance coverage.
Visit RX-O2 in Scottsdale or Glendale. Call 480-270-6090 for Scottsdale or 623-930-0887 for Glendale, or book a consultation online. Booking starts the conversation; medical review determines treatment suitability.
Schedule an RX-O2 consultation in Scottsdale or Glendale and involve the team guiding your cancer care.
This page discusses fourteen selected research publications: six clinical trial or cohort reports, two preclinical studies, five reviews, and one trial protocol. Guidance and safety references complete the source list. The two RICH-ART papers concern the same trial, and reviews may include studies also discussed individually. Protocols and registrations are not evidence of successful treatment.
Literature checked September 11, 2026. This is a source-check date, not an independent physician-review attestation or an exhaustive systematic review. These summaries are educational; a clinical evaluation is needed to discuss individual suitability.
